SCHEDULE: Venrock Group Discloses 9.8% Stake in DBV Technologies
Beneficial Ownership Report
A group of Venrock Healthcare Capital Partners entities and individuals reported a collective 9.8% beneficial ownership stake in DBV Technologies S.A. as of June 30, 2025.
Summary
- A group of ten reporting persons, including Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Y. Koh, collectively beneficially own 14,286,553 shares of DBV Technologies S.A.
- This aggregate ownership represents 9.8% of the issuer's class of Ordinary Shares, EURO0.10 nominal value per share, represented by American Depository Shares (ADSs).
- The beneficial ownership includes a combination of Ordinary Shares represented by ADSs and Pre-Funded Warrants exercisable for additional Ordinary Shares.
- The percentage is calculated based on 136,948,872 Ordinary Shares outstanding as of April 7, 2025, plus 9,150,000 Ordinary Shares issuable upon exercise of the Pre-Funded Warrants.
- The reporting persons explicitly state that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of DBV Technologies S.A.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership report.
Industry Context
This filing indicates a significant investment by a healthcare-focused capital group in a biotechnology company, which is common in the life sciences sector where specialized funds often take substantial equity positions.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 04/07/2025 | Date as of which 136,948,872 Ordinary Shares of the Issuer were reported outstanding in the Issuer's prospectus. |
| 05/29/2025 | Date of the Issuer's prospectus filed with the SEC. |
| 06/30/2025 | Date of event which required the filing of this statement, representing the beneficial ownership calculation date. |
| 08/14/2025 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
DBV Technologies, Venrock Healthcare Capital Partners, Beneficial Ownership, Schedule 13G, American Depository Shares, Pre-Funded Warrants, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.